Table 1.
Characteristics of kidney transplant recipients from the University Hospital of Heidelberg assessed for coronavirus disease 2019 vaccine response
| Characteristics | Kidney Transplant Recipients after First Vaccination, n=73 | Kidney Transplant Recipients after Second Vaccination, n=135 | |||
|---|---|---|---|---|---|
| mRNA,a n=57 | AstraZeneca, n=16 | mRNA/mRNA,b n=109 | AstraZeneca/AstraZeneca, n=17 | AstraZeneca/mRNA,c n=9 | |
| Sample collection, d after vaccination (IQR) | 21 (20–23) | 21 (16–23) | 21 (20–26) | 22 (15–26) | 19 (16–22) |
| Vaccine interval, d, (IQR) | — | — | 35 (25–42) | 62 (62–62) | 62 (62–71) |
| Age, yr, (IQR) | 55 (43–62) | 55 (45–63) | |||
| Women, N (%) | 29 (40) | 50 (37) | |||
| Transplant-related data d | |||||
| Time since transplantation, yr, (IQR) | 5 (2–13) | 7 (3–14) | |||
| First transplant, N (%) | 62 (89) | 111 (85) | |||
| Deceased donor, N (%) | 42 (60) | 72 (55) | |||
| Current immunosuppressive medication,e N (%) | |||||
| CNI | 64 (90) | 125 (93) | |||
| MPA | 58 (82) | 110 (82) | |||
| Azathioprine | 2 (3) | 4 (3) | |||
| mTOR inhibitor | 8 (11) | 11 (8) | |||
| Belatacept | 2 (3) | 2 (2) | |||
| Steroids | 68 (96) | 130 (97) | |||
| Primary kidney disease, N (%) | |||||
| Diabetes or vascular | 10 (14) | 11 (8) | |||
| Polycystic kidney disease | 14 (19) | 24 (18) | |||
| GN | 23 (32) | 47 (35) | |||
| Other | 26 (36) | 53 (39) | |||
| Comorbidities, N (%) | |||||
| Hypertension | 59 (81) | 104 (77) | |||
| Chronic artery disease | 12 (16) | 25 (19) | |||
| Diabetes | 14 (19) | 20 (15) | |||
| Chronic lung disease | 11 (15) | 21 (16) | |||
| Chronic liver disease | 4 (6) | 9 (7) | |||
| Malignancy | 20 (27) | 32 (24) | |||
IQR, interquartile range; —, not applicable; CNI, calcineurin inhibitor; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin.
a
Fifty-seven received BNT162b2 by BioNTech.
b
One hundred and five received BNT162b2 by BioNTech, and four received mRNA-1273 by Moderna.
c
Nine received BNT162b2 by BioNTech.
d
No transplant-related data were available for three patients after the first vaccine dose and for four patients after the second vaccine dose.
e
No data were available on the immunosuppressive regimen for two patients after the first vaccine dose and for one patient after the second vaccine dose.